— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug disc ...

Eli Lilly (LLY) announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.In the study, muvalaplin led to a significant reduction in elevated Lp(a) levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp(a) from baseline to week 12.  Using an intact Lp(a) assay, the reductions in Lp(a) levels were 47.6% for the 10 mg dose, 81.7% ...

关于muvalaplin药物研究成果 - muvalaplin是一种每日口服一次的治疗药物 通过新机制抑制脂蛋白(a)形成 在12周的2期研究中取得积极成果 数据发表于《美国医学会杂志》(JAMA) 并在2024年美国心脏协会(AHA)科学会议上展示 [1] - 在12周的主要终点上 muvalaplin(10mg、60mg和240mg)与安慰剂相比 脂蛋白(a)水平显著降低 采用完整脂蛋白(a)测定法 安慰剂调整后的降低幅度高达85.8% 采用载脂蛋白(a)测定法 降低幅度高达70.0% 具体而言 采用完整脂蛋白(a)测定法 降低幅度分别为47.6%(10mg)、81.7%(60mg)和85.8%(240mg) 采用载脂蛋白(a)测定法 降低幅度分别为40.4%(10mg)、70.0%(60mg)和68.9%(240mg) [2] - muvalaplin还达到了所有三个测试剂量(10mg、60mg和240mg)的次要终点 三个测试剂量在脂蛋白(a)阈值方面具有统计学意义 60mg和240mg剂量在载脂蛋白B降低方面也具有统计学意义 使用完整脂蛋白(a)测定法 在第12周时 达到脂蛋白(a)水平低于125nmol/L的参与者百分比分别为64.2%(10mg)、95.9%(60mg)和96.7%(240mg) 而安慰剂组为6.0% 使用载脂蛋白(a)测定法 达到脂蛋白(a)水平低于125nmol/L的参与者百分比分别为38.9%(10mg)、81.9%(60mg)和77.4%(240mg) 而安慰剂组为3.6% 载脂蛋白B水平在所有剂量下均降低 安慰剂调整后的降低幅度分别为8.9%(10mg)、13.1%(60mg)和16.1%(240mg) [3] - 不良事件在muvalaplin组和安慰剂组相似 与研究药物相关的治疗突发不良事件在安慰剂组中发生率为14.9% 在10mg组中为5.9% 在60mg组中为14.3% 在240mg组中为14.7% 导致研究药物停药的不良事件发生率在各治疗组中从0到8.8%不等 且为分布在各系统器官类别的单一事件 研究中未报告死亡病例 [4] 关于脂蛋白(a)与心血管疾病 - 高水平脂蛋白(a)是动脉粥样硬化性心血管疾病的重要风险因素 全球有超过10亿成年人受影响 当前降胆固醇疗法未被批准用于降低脂蛋白(a)水平 凸显了心血管疾病患者未被满足的需求 [3] - 在美国 约20%的人(约6300万人)有高水平脂蛋白(a) 升高的脂蛋白(a)水平可使心脏病发作风险增加两倍甚至三倍 并与其他心血管问题有关 [3] 关于礼来公司 - 礼来公司正在评估muvalaplin 这是一种有效的多价小分子 通过阻断载脂蛋白(a)和载脂蛋白B之间的初始相互作用来抑制脂蛋白(a)的形成 虽然针对脂蛋白(a)的注射疗法目前处于3期开发阶段(包括礼来公司自己的lepodisiran项目) 但这些是口服疗法的首个积极2期数据 公司很高兴看到这些有希望的结果并期待进一步探索muvalaplin的后续步骤 [3] - 礼来公司是一家将科学转化为治疗方法的制药公司 近150年来一直在开拓改变生命的发现 如今其药物帮助全球数千万人 利用生物技术、化学和基因医学的力量 科学家们正在紧急推进新发现 以解决一些世界上最重大的健康挑战 如重新定义糖尿病护理、治疗肥胖症并减少其最具破坏性的长期影响、推进对抗阿尔茨海默病、为一些最使人衰弱的免疫系统疾病提供解决方案以及将最难治疗的癌症转化为可控制的疾病 [5]

INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer Incyclix will sponsor the trial and Lilly will provide Verzenio Incyclix plans to initiate combination cohorts with INX-315 in fourth quarter of 2024 RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle ...

The drugmaker Ely Lilly (LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well this year, rising roughly 36% (as of Nov. 14), ahead of the broader market.Given that Eli Lilly has been public for roughly seven decades, it's no surprise that it has conducted a few stock splits. When a company does a split, the amount of a shareholder's equity doesn't change but the number of shares does. Comp ...

关于SUMMIT试验 - 试验基本情况是多中心随机双盲平行安慰剂对照3期研究比较tirzepatide与安慰剂在成人HFpEF和肥胖患者中的疗效和安全性731名参与者按1:1比例接受tirzepatide或安慰剂[9][10] - 主要终点方面tirzepatide达到两个主要终点在降低心力衰竭结果风险方面相对风险降低38%心力衰竭住院风险降低56%在改善心力衰竭症状和身体限制方面KCCQ - CSS评分提高近25分安慰剂组提高15分[2] - 次要终点方面tirzepatide治疗患者运动能力提高6分钟步行距离比安慰剂组远约30米体重平均降低15.7%安慰剂组为2.2%高敏C反应蛋白显著降低43.4%安慰剂组降低3.5%[7] - 安全性方面tirzepatide最常见不良事件主要是胃肠道相关且一般为轻至中度与安慰剂相比腹泻恶心便秘更常见不良事件导致23名tirzepatide组和5名安慰剂组患者停止研究治疗[7] 关于tirzepatide - 药物性质方面tirzepatide是一种每周一次的GIP和GLP - 1受体激动剂单一分子激活身体的GIP和GLP - 1受体减少卡路里摄入可能通过影响食欲起作用[12] - 已获批情况tirzepatide于2022年5月13日被美国FDA批准为Mounjaro用于成人2型糖尿病改善血糖控制2023年11月8日被批准为Zepbound用于成人肥胖或超重且至少有一个与体重相关的医疗问题[13] - 提交审批情况公司已向美国FDA和欧洲药品管理局提交tirzepatide用于治疗HFpEF和肥胖症并计划今年晚些时候向其他监管机构提交[8] 关于Mounjaro和Zepbound - Mounjaro是用于成人2型糖尿病的注射药物与饮食和运动一起使用改善血糖使用有多种注意事项和警告包括可能的副作用如胰腺炎低血糖等[36][39][40][41] - Zepbound是用于成人肥胖或超重且有体重相关医疗问题的注射药物帮助减轻体重应与低热量饮食和增加体育活动一起使用也有多种注意事项和警告如甲状腺肿瘤等[15][16][18][19]

Key TakeawaysEli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities, needs changes.The Health Resources and Services Administration, however, has rejected the companies' proposed changes to the program. Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting t ...

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three yearsResults suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatideParticipants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose)INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study ...

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.Finding stocks that could quickly double or triple your money isn't hard. Just about every day, a Wall Street analyst issues a price target that suggests a relatively small and unestablished company could double or triple your money. Usually, though, the word "could" is working way too hard for such a risky investment to make sense for most investors.If you want to avoid the riskiest corners of the stock ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNALEli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 10:35 AM on November 12th, a significant trading signal occurred for Eli Lilly as it demonstrated a Power Inflow at a price of $816.14. This indicator is crucial for traders who want to know directionally where institutions and so-calle ...